Stifel Financial Corp Sells 41,819 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

Stifel Financial Corp lessened its position in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 25.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 122,448 shares of the company’s stock after selling 41,819 shares during the quarter. Stifel Financial Corp’s holdings in X4 Pharmaceuticals were worth $82,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Bank of New York Mellon Corp raised its stake in shares of X4 Pharmaceuticals by 39.7% in the second quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock valued at $272,000 after acquiring an additional 133,398 shares during the period. Rhumbline Advisers raised its holdings in shares of X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after acquiring an additional 23,831 shares in the last quarter. XTX Topco Ltd bought a new position in shares of X4 Pharmaceuticals in the 2nd quarter worth $65,000. Ensign Peak Advisors Inc boosted its holdings in shares of X4 Pharmaceuticals by 4.6% in the 2nd quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after buying an additional 111,032 shares in the last quarter. Finally, K2 Principal Fund L.P. acquired a new position in shares of X4 Pharmaceuticals during the second quarter worth $284,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other X4 Pharmaceuticals news, COO Mary Dibiase sold 67,695 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $0.57, for a total transaction of $38,586.15. Following the completion of the sale, the chief operating officer now owns 452,060 shares of the company’s stock, valued at $257,674.20. This trade represents a 13.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam S. Mostafa sold 230,645 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $0.55, for a total value of $126,854.75. The disclosure for this sale can be found here. Insiders have sold 580,800 shares of company stock valued at $321,447 in the last ninety days. 1.62% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have issued reports on XFOR. Stifel Nicolaus decreased their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, November 14th. HC Wainwright cut their price target on X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating on the stock in a research report on Thursday, November 14th.

X4 Pharmaceuticals Trading Up 0.5 %

Shares of XFOR stock opened at $0.81 on Tuesday. The firm has a market capitalization of $137.82 million, a P/E ratio of -8.98 and a beta of 0.35. X4 Pharmaceuticals, Inc. has a fifty-two week low of $0.26 and a fifty-two week high of $1.60. The stock’s fifty day moving average is $0.52 and its two-hundred day moving average is $0.63. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89.

X4 Pharmaceuticals Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.